Shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) shot up 2.4% on Friday . The company traded as high as $3.42 and last traded at $3.38. 23,741 shares changed hands during trading, a decline of 92% from the average session volume of 286,469 shares. The stock had previously closed at $3.30.
Pasithea Therapeutics Trading Up 2.4 %
The company’s fifty day moving average price is $4.25 and its 200-day moving average price is $5.07.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Featured Articles
- Five stocks we like better than Pasithea Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- How to Plot Fibonacci Price Inflection Levels
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Time to Load Up on Home Builders?
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
